Posted on 2/21/2012 by meg
Ontario’s recent decision to eliminate oxycontin and delist its replacement, oxyneo, from the Ontario Drug Benefit program sends a powerful message across the province; that something needs to be done about this epidemic addiction to prescription painkillers.
Oxyneo is a tablet that is purposely difficult to crush and forms into a thick gel when added to liquid to prevent oxycodone from being extracted for use by injection.
Basically, oxycontin will no longer be manufactured in Canada and it will be replaced with a new formulation called oxyneo by the end of February 2012. Additionally, the Ontario Drug Benefit program will not list oxyneo in their formulary; therefore no coverage will exist for those using this program to fund their habit.
Dr. Irfan Dhalla of Toronto’s St. Michael’s Hospital discovered a spike in opioid-related deaths, which coincided with the addition of long-acting oxycodone to Ontario’s drug plan in 2000.
The Ontario Drug Benefit Program (ODB) offered through the Ministry of Health and Long Term Care (MOHLTC) covers most of the cost of prescription drug products listed in the ODB Formulary. It is available to people 65 years of age and older, residents of long-term care homes and Homes for Special Care, people receiving professional services under the Home Care program, Trillium Drug Program registrants and people in receipt of Ontario Works or Ontario Disability Support Program assistance.
That being said, the drug will still be available to certain individuals through the Exceptional Access Program (EAP). This program facilitates patient access to drugs not funded on the ODB Formulary, or where there is no listed alternative available. To apply for funding through the EAP, a physician must submit a request, which documents all complete and relevant medical information that provides a clinical rationale for requesting coverage including the reason(s) that other similar listed drugs are not suitable. All requests are reviewed according to the guidelines put forth by the ministry’s expert advisory committee, the Committee to Evaluate Drugs (CED), which thoroughly assesses each patient’s specific case and clinical circumstances.
In short, oxycontin will no longer be available commercially in Canada and its replacement, oxyneo, will be under more strict regulations in Ontario so that it is less available to just anyone under the ODB, thereby making it less easily abused.
However, with such great strides comes a myriad of problems when all these individuals begin to experience withdrawal. As major changes are being seen at the provincial level only, neighbouring provinces may have less or no restrictions on oxyneo, which may encourage smuggling. For instance, “Manitoba and British Columbia are among a handful of provinces that have yet to decide whether to fund OxyNeo once OxyContin is discontinued” yet Prince Edward Island and New Brunswick, like Ontario, have chosen not to pay for the new drug. Nevertheless, to avoid such great lengths, addicts may simply turn to other prescription drugs.
There is a high risk of experiencing severe withdrawal symptoms if a patient discontinues oxycodone abruptly. Therefore therapy should be discontinued gradually rather than abruptly. People who use oxycodone in a hazardous or harmful fashion are at even higher risk of severe withdrawal symptoms as they tend to use higher than prescribed doses. The symptoms of oxycodone withdrawal are the same as for other opiate based painkillers and may include "anxiety, panic attack, nausea, insomnia, muscle pain, muscle weakness, fevers, and other flu like symptoms.”Clearly prohibiting this drug in itself will not fix the problem. Perhaps the savings from delisting this drug could be more appropriately used to fund treatment programs across the province…
OxyContin limits lauded
Exceptional Access Program (EAP)
Ontario Drug Benefit: The Program
(+)-naloxone 6-acetylmorphine (6AM) Addiction Adenovirus Adolescence Adrenaline Aftershave Airplaning Alcohol Alcohol Poisoning Alcoholic Alcoholism Amphetamine Anaplasticity Anterior Cingulate Cortex Antibodies Anxiety Appetite Assault Attention Bath Salts Battery Acid Beer Belfast Benefits Benzoylmethylecgonine Bergen Facebook Addiction Scale Binge Drinking Biochemical Biological Clock Body Language Bone Fracture Bones Bonsai Grow Boot Camp Brain Brain Damage Break-Up British Columbia Bum Rushing Buprenorphine California Dreaming Canada Cancer Casino Cathinones Centers for Disease Control and Prevention China Choking Game Cigarette Circadian Rhythm Cirrhosis Citric Acid Cloud Nine Cocaine Cocaine Vaccine Cognitive Behavioral Therapy Common Cold Compulsivity Constitutional Right Content-Control Software Counselor Crack Craving Cues Death Decision-Making Demerol Dentist Dependence Dependency Depression Dilaudid Dopamine Dr. Drew Drain Cleaner Drug E-Cigarette Electric Shock Electronic Cigarette Emotion Employment Programs Engrams Exceptional Access Program (EAP) Facebook Facebook Addiction Failure Fainting Game Family Finances Flat Liner fMRI France Funky Chicken Gamblers Anonymous Gambling Genes Glutamate Government Grey Matter Hapten Harm Reduction Harvey Wallbanger Health Health Care Heart Attack Heart Disease Heroin Hillbilly Heroin HIV/AIDS Homelessness Hospitalization Human Rights Hunger Hurricane Charlie Hydrocodone Hydromorphone Hygiene Hypothalamus Illicit Drug Use Immune System Immune-Addiction Response Immunopharmacotherapy Implant Impulse Control Disorders Injection Injuries Instinct Internet Addiction Internet Gambling Intervention Ivory Wave Jay Leno Knockout Game Lantern Fuel Liver Long Term Depression Love Ludomania MADD Medial Prefrontal Cortex Medication Memories Memory Memory Traces Meperidine Mephedrone Mesolimbic Reward Pathway Methadone Methamphetamine Methylenedioxypyrovalerone (MDPV) Methylone Mid-Brain Money Montreal Morphine Motivation Mouthwash mRNA Muscle Control Naloxone Naltrexone Narcotic Negative Consequences Neural Pathway Nicotine Nicotine Gum Nicotine Patch Noradrenalin Norepinephrine Obsessive-Compulsive Online Gambling Ontario Disability Support Program (ODSP) Ontario Drug Benefit (ODB) Ontario Works (OW) Opiate Opioid Oral Hygiene Orbitofrontal Cortex Osteoporosis Ottawa Overdose Oxycodone Oxycontin Oxyneo Pain Pain Management Painkiller Paint Thinner Pass-out Game Pathological Computer Use Pathological Gambling Percocet Placebo Poker Pop Pre-frontal Cortex Prefrontal Cortex Prescription Drugs Propoxyphene Psychoactive Purple Dragon Rats Recovery Red Dove Rehab Rejection Relapse Relationships Research Research Validity Reward Reward and Punishment Risky Sexual Behavior RNA Safe Injection Site Salt Scarface Sensory Perception Serotonin Sex Addiction Shame Sleep/Wake Cycle Sleeper Hold Slot Machines Smoking Smoking-Cessation SNDRI Sobriety Social Assistance Social Media Social Security Soda Soda Addiction Sodium Sodium Ion Channel Space Monkey Speech Star Dust Striatum Subutex Successful Treatment Supreme Court of Canada Synapse Teenagers Tobacco Toll-Like receptor 4 (TLR4) Tooth Decay Tooth Enamel Tooth Erosion Treatment Trillium Drug Program Urine Sample Vaccine Vancouver Vanilla Sky Vaporize Vicodin Virus Vivitrol Welfare Wet Program White Lightning White Matter Wine Withdrawal